Monday, November 12, 2012
Now that the elections are
over, Congress, President Obama and his administration may finally turn their
attention to urgent decisions that will determine the size and health of the
two poles of the biomedical R&D universe: the basic research that fuels
discovery at one end, and at the other, the revenues that are essential for
continued investment in innovative products.
Washington's to-do list for the
remaining weeks of 2012 includes forestalling, modifying or acquiescing to the
enactment of sequestration, the across-the-board budget cuts that could cripple
American science for a generation and limit FDA's ability to modernize.